Patenton — panteon of patents

(19)

RU

(11)

2 585 489

(13)

C2

(51)

IPC

A61K39/395(2006-01-01)

A61K31/436(2006-01-01)

A61P35/00(2006-01-01)

(21) (22)

Application

2012147340/10, 2011-04-21

(24)

Start date

2011-04-21

(22)

Actual filing date

2011-04-21

(45)

Published

2016-05-27

(72)

Inventor

Gerting FrankKlyajn Kristian

(73)

Holder

Rosh Glikart Ag

COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR Russian patent published in 2016 - IPC A61K39/395 A61K31/436 A61P35/00 

Abstract RU 2585489 C2

FIELD: biochemistry.

SUBSTANCE: invention relates to a combined therapy with afucosylated anti-CD20 antibody and mTOR inhibitor for treating cancer. Disclosed is use of afucosylated humanised anti-CD20 B-Ly1 antibody for preparing a drug for treating B-cell non-Hodgkin lymphoma in combination with mTOR inhibitor, such as temsirolimus or everolimus.

EFFECT: invention enables to achieve synergetic anti-proliferative effect in treating cancer.

2 cl, 1 dwg, 3 tbl

Similar patents RU2585489C2

Title Year Author Number
COMBINED THERAPY BY AFUCOSYLATED ANTIBODY FOR CD20 WITH ANTIBODY FOR VEGF 2011
  • Gerting Frank
  • Klyajn Kristian
 RU2615459C2
COMBINED THERAPY BASED ON CD20 ANTIBODY AND BTK INHIBITOR 2014
  • Klajn Kristian
  • Toshio Joshizava
  • Tomoko Yasukhiro
 RU2727650C2
COMBINED THERAPY BASED ON CD20 ANTIBODY COMBINED WITH BCL-2 INHIBITOR AND MDM2 INHIBITOR 2016
  • Klyajn Kristian
  • Kherting Frank
  • Dangl Markus
 RU2727196C2
COMBINATION THERAPY BASED ON ANTI-CD20 ANTIBODY AND BTK INHIBITOR 2021
  • Klein Christian
  • Toshio Yoshizawa
  • Tomoko Yasuhiro
 RU2815679C2
COMBINATION THERAPY WITH NON-FUCOSYLATED ANTI-CD20 ANTIBODY AND BENDAMUSTINE 2010
  • Frank Kherting
  • Kristian Klajn
 RU2575820C2
COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION 2014
  • Klajn Kristian
  • Lang Zabine
  • Polson Endryu
  • Umana Pablo
 RU2700092C2
COMBINATION THERAPY OF AFUCOSYLATED CD20 ANTIBODY WITH CD79b ANTIBODY-DRUGS CONJUGATE 2014
  • Klajn Kristian
  • Lang Zabine
  • Polson Endryu G.
  • Umana Pablo
 RU2670971C9
USING ANTI-CD20 TYPE II ANTIBODY, HAVING HIGH ANTIBODY-INDUCED CELL-DEPENDENT CYTOTOXICITY (ADCC), COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICIN FOR TREATING NON-HODGKIN LYMPHOMAS 2009
  • Sharl Dyumonte
  • Tomas Friss
  • Frank Kherting
  • Kristian Klajn
  • Pablo Umana
 RU2589704C2
ANTIBODY PREPARATION 2008
  • Adler Mikhaehl'
  • Maler Khans-Kristian
  • Vjurt Kristin
 RU2476238C2
COMBINED THERAPY WITH TYPE II ANTI-CD20 ANTIBODIES IN COMBINATION WITH PROTEASOME INHIBITOR 2008
  • Georg Fertig
  • Tomas Friss
  • Kristian Klajn
  • Pablo Umana
 RU2520757C2

RU 2 585 489 C2

Authors

Gerting Frank

Klyajn Kristian

Dates

2016-05-27—Published

2011-04-21—Filed

download Download PDF read Similar patents